CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate...
Phase 1
Durham, North Carolina, United States and 7 other locations
ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate...
Phase 2
Durham, North Carolina, United States
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also de...
Chapel Hill, North Carolina, United States and 7 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Raleigh, North Carolina, United States and 107 other locations
Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for me ...
Phase 1
Durham, North Carolina, United States and 13 other locations
inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficie...
Phase 2
Durham, North Carolina, United States and 11 other locations
This study will enroll prostate cancer patients with an unfavorable diagnosis. Subjects will receive a combination of pembrolizumab...
Phase 2
Durham, North Carolina, United States
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stim...
Phase 3
Durham, North Carolina, United States and 72 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Durham, North Carolina, United States and 131 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Durham, North Carolina, United States and 50 other locations
Clinical trials
Research sites
Resources
Legal